Temocillin - Eumedica Pharmaceuticals

Drug Profile

Temocillin - Eumedica Pharmaceuticals

Alternative Names: Negaban; Temopen

Latest Information Update: 07 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antibacterials; Penicillins
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections
  • No development reported Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 21 Apr 2018 Antimicrobial data from a study in Bacterial infections presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases
  • 16 Apr 2003 No development reported - Clinical-Phase-Unknown for Cystic fibrosis-associated respiratory tract infections in United Kingdom (Parenteral)
  • 16 Apr 2003 No development reported - Preclinical for Cystic fibrosis-associated respiratory tract infections in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top